This article has been updated with comments from company officials.

NEW YORK (GenomeWeb News) – Illumina today announced that it has acquired Cambridge, UK-based BlueGnome for an undisclosed sum.

The deal provides Illumina with BlueGnome's array-based cytogenetic and in vitro fertilization screening tests. The firm's 24sure test is a preimplantation genetic screening assay for counting the chromosomes in a single human cell and "holds enormous promise for increasing IVF success rates," said Illumina.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.